AT1 receptor blockade prevents interstitial and glomerular apoptosis but not fibrosis in pigs with neonatal induced partial unilateral ureteral obstruction.
Obstruction-induced fibrosis is a leading cause of end-stage renal failure in children. The pathophysiological mechanisms may involve apoptosis and the renin-angiotensin system. We studied apoptosis and fibrosis in a well-established neonatal pig model with unilateral partial ureteral obstruction (PUUO) induced during ongoing nephrogenesis in 2-day-old piglets. The role of angiotensin II (ANG II) was studied using the AT(1) receptor blocker CV-11974 (0.12 mg/h candesartan from age 23 to 30 days). At day 30 the kidneys were perfusion fixed and fibrosis, apoptosis, and tubular lengths were quantitated using stereological methods, picro Sirius red staining, and immunohistochemical techniques identifying activated caspase 3, aquaporin-2 (AQP2), and von Willebrand factor. The collagen content was assessed by hydroxyproline density. Neonatal induced PUUO increased interstitial and glomerular cell apoptosis and fibrosis. At this stage, PUUO did not increase tubular cell apoptosis or decrease tubular length and cell number. AT(1) receptor blockade prevented the PUUO-induced interstitial and glomerular cell apoptosis but did not attenuate fibrosis. In conclusion, AT(1) receptor blockade after the end of nephrogenesis may prevent interstitial and glomerular cell apoptosis but not fibrosis, suggesting that pathways not involving AT(1) receptor stimulation contribute to neonatal obstruction-induced fibrosis or that prevention of interstitial cell apoptosis counteracts a potential antifibrotic effect of AT(1) receptor blockade in this pig model of congenital obstructive nephropathy. Our results demonstrate that ANG II plays a role in PUUO-induced glomerular cell apoptosis.
Eskild-Jensen
Anni
A
Department of Clinical Physiology and Nuclear Medicine, Aarhus University Hospital, Aarhus C, Denmark. aej@ki.au.dk
Paulsen
Lene Fogt
LF
Wogensen
Lise
L
Olesen
Ping
P
Pedersen
Lea
L
Frøkiaer
Jørgen
J
Nyengaard
Jens Randel
JR
D000804:Angiotensin II / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects*; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D002196:Capillaries / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D002452:Cell Count; D003094:Collagen / Q000096:biosynthesis; D005260:Female; D005355:Fibrosis; D006909:Hydroxyproline / Q000032:analysis / Q000378:metabolism; D007150:Immunohistochemistry; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology*; D007684:Kidney Tubules / Q000166:cytology; D009395:Nephritis, Interstitial / Q000473:pathology*; D013552:Swine; D013777:Tetrazoles / Q000494:pharmacology; D016707:Tissue Fixation; D014517:Ureteral Obstruction / Q000473:pathology*
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000804:Angiotensin II; D003094:Collagen; D053148:Caspase 3; D006909:Hydroxyproline; C081643:candesartan